The estimated Net Worth of David Brannon Johnston is at least $6.26 Million dollars as of 6 June 2018. David Johnston owns over 10,000 units of Immunogen stock worth over $5,957,156 and over the last 14 years David sold IMGN stock worth over $306,453.
David has made over 18 trades of the Immunogen stock since 2011, according to the Form 4 filled with the SEC. Most recently David exercised 10,000 units of IMGN stock worth $30,500 on 6 June 2018.
The largest trade David's ever made was selling 21,060 units of Immunogen stock on 21 February 2018 worth over $228,922. On average, David trades about 3,667 units every 89 days since 2011. As of 6 June 2018 David still owns at least 190,690 units of Immunogen stock.
You can see the complete history of David Johnston stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., and Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: